Cardiovascular Health Topics

The On-Topic Netowork

Cardiovascular Health > Arrhythmia

The following information is about Arrhythmia.

Arrhythmia Defined

A generic term that refers to a change in the rate or rhythm of the heart. These changes may be a slowing of heart beats, or a rapid beating, or a brief pause of the heart beat, or irregular heart beats.

This definition is in context to Cardiovascular Health. See more contextual defintions for Arrhythmia.


Navigation: [ 1 2 Next ]

FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter

Published July 3, 2009, 5:07 am, Medical News Today

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease.

Full Story


Sanofi-Aventis arrhythmia drug Multaq approved

Published July 2, 2009, 3:45 pm, INO News

(AP:TRENTON, N.J.) Sanofi-Aventis SA said Thursday its drug Multaq, which treats irregular heart rhythms, received marketing approval from the Food and Drug Administration, which turned it down three years ago.

Full Story


Sanofi-Aventis arrhythmia drug Multaq approved

Published July 2, 2009, 9:58 am, INO News

(AP:NEW YORK) Sanofi-Aventis SA said Thursday its drug Multaq, which treats irregular heart rhythms, received marketing approval after a delay of nearly three years.

Full Story


FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter

Published July 2, 2009, 7:46 am, redOrbit

PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets.

Full Story


FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter

Published July 2, 2009, 6:05 am, PR Newswire via Yahoo! Finance

Sanofi-aventis announced today that the U.S. Food and Drug Administration has approved Multaq® 400 mg Tablets. Patients with atrial fibrillation or atrial flutter soon will have a new treatment option to help improve current management of their disease.

Full Story


FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter

Published July 2, 2009, 1:26 am, FinanzNachrichten

Paris (ots/PRNewswire) - - Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter ...

Full Story


FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter

Published July 2, 2009, 1:14 am, Presseportal

Paris (ots/PRNewswire) - - Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter - U.S Commercial Launch Planned for the Summer of 2009 ...

Full Story


FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter

Published July 2, 2009, 1:12 am, ITNews

PARIS, July 2 /PRNewswire/ -- - Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter - U.S Commercial Launch Planned for the Summer of 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets.

Full Story


Enzyme Doesn't Act Alone In Atrial Fibrillation

Published June 30, 2009, 6:20 pm, Science Daily

An overactive enzyme is behind a leaky calcium channel that plays a role in the development of atrial fibrillation, which is the most common cardiac arrhythmia that is responsible for a third of all strokes. However, it doesn't act alone, say researchers.

Full Story


UCI Cardiology Chief Jagat Narula, MD, Named Memorial Heart and Vascular Institute Medical Director

Published June 30, 2009, 9:00 am, Business Wire via Yahoo! Finance

LONG BEACH, Calif.----Officials at Long Beach Memorial Medical Center have named world-renowned researcher and cardiologist Jagat Narula, MD, PhD, FACC, FRCP, medical director of the Memorial Heart and Vascular Institute , effective immediately.

Full Story


Navigation: [ 1 2 Next ]

Are you looking for additional Cardiovascular Health > Arrhythmia news? Try our new "Arrhythmia News Focus" area.

Off-site Arrhythmia Links, User Submitted

The following links have been collected through user bookmark submission in the Arrhythmia category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Thu Jul 2

  • Developmental Basis for Electrophysiol ogical Heterogeneity in the Ventricular and Outflow Tract Myocardium As a Substrate for Life-Threateni ng Ventricular Arrhythmias -- Boukens et al. 104 (1): 19 -- Circulation Research: Reentry is the main mechanism of life-threateni ng ventricular arrhythmias, including ventricular fibrillation and tachycardia. Its occurrence depends on the simultaneous presence of an arrhythmogenic substrate (a preexisting condition) and a "trigger, " and is favored by electrophysiol ogical heterogeneitie s. In the adult heart, electrophysiol ogical heterogeneitie s of the ventricle exist along the apicobasal, left?right, and transmural axes. Also, conduction is preferentially slowed in the right ventricular outflow tract, especially during pharmacologica l sodium channel blockade. We propose that the origin of electrophysiol ogical heterogeneitie s of the adult heart lies in early heart development. The heart is formed from several progenitor regions: the first heart field predominantly forms the left ventricle, whereas the second heart field forms the right ventricle and outflow tract. Furthermore, the embryonic outflow tract consists of slowly conducting tissue until it is incorporated in
  • Molecular Basis of Arrhythmias -- Shah et al. 112 (16): 2517 -- Circulation: The characterizati on of single gene disorders has provided important insights into the molecular pathogenesis of cardiac arrhythmias. Primary electricalal diseases including long-QT syndrome, short-QT syndrome, Brugada syndrome, and catecholaminer gic polymorphic ventricular tachycardia have been associated with mutations in a variety of ion channel subunit genes that promote arrhythmogenes is. Pathological remodeling of ionic currents and network properties of the heart critical for normal electrical propagation plays a critical role in the initiation and maintenance of acquired arrhythmias. This review focuses on the molecular and cellular basis of electrical activity in the heart under normal and pathophysiolog ical conditions to provide insights into the fundamental mechanisms of inherited and acquired cardiac arrhythmias. Improved understanding of the basic biology of cardiac arrhythmias holds the promise of identifying new molecular targets for the treatment of cardiac arrhythmias.
  • Inherited Arrhythmogenic Diseases: The Complexity Beyond Monogenic Disorders -- Priori 94 (2): 140 -- Circulation Research: Twelve years after the identification of the molecular bases of the long-QT syndrome, it is now possible to express some considerations on the impact that genetic findings have had in the understanding of inherited arrhythmogenic diseases. Along with the excitement for the emerging data on genotype/pheno type correlation and for the development of the first recommendation s for gene-specific management of patients, it is also important to acknowledge the unexpected complexity that has emerged. The focus of this article is to analyze the elusive aspects of the relationship between genetic defects and clinical manifestations and to propose some research directions that may provide the needed answers to move forward in the understanding of the genetics of heart rhythm abnormalities.

Wed Jul 1

  • MedicalMommas. com Moment: SVT: Dr. John Clark, Akron Children' s Hospital pediatric cardiologist, discusses symptoms and solutions for Superventricul ar Tachycardia (SVT) on MedicalMommas. com.
  • MedicalMommas. com AskMe: SVT: MedicalMommas. com co-founder, Diana Keough chats with Dr. Grace Smith, Akron Children' s Hospital pediatric cardiologist, about kids' heart conditions.
  • MedicalMommas. com MyStory: Diana and Bret Keough: MedicalMommas. com Editor-in-Chie f, Diana Keogh, and her son, Bret, share about how they dealt with Bret's SVT diagnosis and surgery.
  • It's Kind of a Big Deal: Bret Keough, who was diagnosed with SVT three years ago, shares his experience with the diagnosis and surgery. He also offers tips to parents and kids in similar situations.
  • When a Medical Story Hits Home: Medical Journalist and Editor-in-Chie f of MedicalMommas. com, Diana Keough, shares about when her son was diagnosed with Supraventricul ar Tachycardia and had to undergo heart surgery at 15 years old.

Sun Jun 14

If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Arrhythmia. If you would like to find related tags we recommend Tag Patterns > Arrhythmia

Off-site Arrhythmia Research Links

If you still need additional information on Arrhythmia then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Cardiovascular Health

If you know the Cardiovascular Health Term Name use the links below to quickly jump to your desired focus.



Bookmark Us

The On Topic Network

This website is part of The On Topic Network.

Thank You

Cardiovascular-Health.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.

License

Creative Commons License This work is licensed under Creative Commons.


Your Ad Here
Your Ad Here

Powered by Odin Assemble 2.5a